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As the coronavirus disease 2019 (COVID-19) outbreak has rapidly evolved into a
global pandemic, abdominal organ transplantation programs are currently facing multiple
challenges. Transplant candidates and recipients are considered high-risk populations for
severe disease and death due to COVID-19 as a result of their numerous underlying
comorbidities, advanced age and impaired immune function. Emerging reports of
atypical and delayed clinical presentations in these patients generate further concerns
for widespread disease transmission to medical personnel and the community. The
striking similarities between COVID-19 and other outbreaks that took place over the
past two decades, like Severe Acute Respiratory Syndrome and Middle East Respiratory
Syndrome, highlight the severity of the situation and dictate that extra measures
should be taken by the transplant programs to avoid adverse outcomes. Transplant
organizations are currently calling for strict screening and isolation protocols to be
established in all transplant programs, for both organ donors and recipients. As the
situation escalates, more radical measures might be necessary, including a temporary
hold on non-urgent transplantations, resulting in serious ethical dilemmas between the
survival of these patients and the safety of the community. Further data about these
special populations could result in more individualized guidelines for abdominal organ
transplantation in the era of COVID-19.
Keywords: coronavirus, liver transplantation, kidney transplantation, immunosuppression, super-spreading
events

INTRODUCTION
In late December 2019, a series of pneumonia of unknown origin emerged in the
city of Wuhan, China. The pathogen was identified to be a novel enveloped RNA
betacoronavirus named SARS-CoV-2 (Severe Acute Respiratory Syndrome coronavirus 2)
(1). The viral disease, named COVID-19 (coronavirus disease 2019), was declared as a
pandemic by the World Health Organization on March 11th, 2020 (2). By May 21st,
2020, there were over 4,800,000 confirmed cases, more than 320,000 deaths attributed
to the disease, and 216 countries and territories have been affected worldwide (3).
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TABLE 1 | Demographic and management characteristics of COVID-19 case series including abdominal organ transplant recipients.

Immunosuppression
tapered/stopped

According to a report by the Chinese Center of Disease Control
and Prevention (CCDC), the manifestations of SARS-CoV-2
laboratory-confirmed infection varied from asymptomatic/mild
disease (81%) to severe disease (14%), and critical disease (5%)
(6). The clinical presentation most commonly consists of fever
(>85%), cough (>65%), myalgia, or fatigue (>40%) (4, 5, 7).
A minority of patients (<15%) develop headache, confusion,
and chills, while gastrointestinal symptoms (nausea, vomiting,
and diarrhea) are less common (4, 7). Common imaging
findings include bilateral patchy shadowing on chest radiography
and ground glass appearance on computed tomography, while
lymphocytopenia (>80%) was the most characteristic laboratory
finding (7). According to the report of the first case series
from China, a significant proportion of patients (23.7%) suffered
from comorbidities, which are commonly seen in abdominal
transplant candidates, including hypertension (15.0%), diabetes
mellitus (7.2%), hepatitis B infection (2.1%), cancer (0.9%),
chronic kidney disease (0.7%) and immunodeficiency (0.2%) (7).
In another case series, Wang et al. reported that the patients
with the aforementioned comorbidities were also more likely
to become critically ill and be admitted to the ICU (8), while
according to the CCDC data, their case fatality rate was much
higher compared to the overall rate of 2.4% (6). The same
conclusions were also drawn for older patients (aged 70 and
above). These associations were later confirmed in a large study
of 1,590 Chinese patients (9). In addition, a more rapid disease
progression from symptom onset to death has been described in
the elderly (10).
The potential implications of these findings for abdominal
organ transplant candidates and recipients are particularly
evident. Transplant recipients are most often on life-long
immunosuppressants, which predispose them to infections,
while transplant candidates usually have a combination of
underlying comorbidities and tend to be older compared
to the general population. Renal transplant candidates on
dialysis are repeatedly undergoing hemodialysis sessions in
centers permitting potential exposure and re-exposure of this
vulnerable to the virus population with the above-mentioned
comorbidities (11). Liver candidates are also at higher risk
as decompensated cirrhotics are more prone to infections
in general, while most patients with end-stage liver disease
awaiting liver transplantation in the U.S. are in their sixth
or seventh decade of life (12). That being said, the Wuhan
group did not report a higher risk in this population (13). The

HCQ

CLINICAL CHARACTERISTICS AND
OUTCOMES—ARE ABDOMINAL ORGAN
TRANSPLANT RECIPIENTS AND
CANDIDATES AT INCREASED RISK?

LPV/r

COVID-19 Management

Tocilizumab

The novel coronavirus is associated with a high risk of acute
respiratory disease and Intensive Care Unit (ICU) admission
(4, 5). It is hard to project the future dynamics of this pandemic
and its long-term impact on worldwide healthcare. In this mini
review, we aimed to examine the potential effects of the COVID19 pandemic on abdominal organ transplantation.

1/15 (6.7)

COVID-19 and Abdominal Organ Transplantation

1/18 (5.6)

Esagian et al.

June 2020 | Volume 7 | Article 287

Esagian et al.

COVID-19 and Abdominal Organ Transplantation

CDC has, therefore, classified elderly and immunocompromised
patients, including transplant recipients, as high-risk patients for
severe COVID-19 disease (14). Multiple COVID-19 case series
including abdominal organ transplant recipients have recently
been published (15–20). The characteristics of these studies
are presented in Table 1, while their results are presented in
Table 2. A common finding among these studies was that the
rates of all adverse outcomes recorded were significantly higher
compared to the general population, as expected. The majority
of patients were hospitalized and had radiographic evidence of
pneumonia. A significant proportion required ICU admission
or mechanical ventilation and the case fatality rates recorded
were up to 10 times higher compared to those of the general
population. However, most of these case series had small samples,
thus precluding us from drawing robust conclusions. Another
consideration is that confounding factors may have influenced
the outcomes in these studies. These include but are not limited to
advanced age, high proportion of males, different time intervals
between transplantation and infection, and different approaches
to immunosuppression tapering or antiviral treatment. All these
factors may have adversely affected patient outcomes, and
could potentially explain some of the differences between these
studies. More robust evidence is needed, in the form of large
population-based studies and clinical trials, to further explore
these associations and create individualized guidelines for
patient management.
Respiratory viral infections are common in solid organ
transplant recipients and often present atypically (21). Although
data for abdominal organ transplant candidates and recipients
are still limited, emerging reports have indicated that these
patients may present with atypical COVID-19 manifestations.
In two individual case reports, two kidney transplant recipients
presented with mild gastrointestinal symptoms and no fever.
Notably, the patients’ temperature remained relatively low
(<38.0◦ C) for several days, and severe symptoms did not
manifest until after the first week of illness in both cases (22, 23).

In a similar case, poor appetite was the only initial symptom and
fever did not develop until 6 days later (24). In two other kidney
transplant recipients, fever was present at onset but remained
low (<38.0◦ C) throughout the course of the disease (25, 26).
Another kidney transplant recipient did not develop any fever or
respiratory symptoms, despite the presence of imaging findings
compatible with pneumonia (27). In a case series from the U.S.,
only 58.3% of the patients (n = 21/36) had fever and 52.8% (n =
19/36) had cough, the two most common COVID-19 symptoms
(19). We can hypothesize that the immunosuppression regimens
of these patients might have altered the expected disease course.
Besides the presumed increased susceptibility and case fatality,
these findings generate additional concerns regarding this patient
population. This mild initial course of illness requires very
high clinical suspicion and can set the stage for the so-called
“super-spreading” events, similar to other viral outbreaks that
can put the community at significant risk before appropriate
isolation measures are taken (28). The possibility of false negative
testing increases this concern (29). An example is a kidney
transplant recipient who presented with mild symptoms only and
initially tested negative for the virus (25). Transplant recipients
are also susceptible to various common respiratory infections
due to their immunosuppression regimens. Consequently, when
these patients present with respiratory symptoms, the differential
diagnosis can become overly complicated and could potentially
delay appropriate care (23). This became evident in a case of a
liver transplant recipient; COVID-19 diagnosis and appropriate
care were delayed due to the patient’s atypical presentation and
overlapping findings with seasonal influenza (30). In contrast to
the previous findings, other case series suggest that COVID-19 in
abdominal organ transplant recipients presents the same way as
it does in the general population (15–17). The aforementioned
concerns for missed cases due to false negative testing or
misdiagnosis should be strongly considered when interpreting
epidemiologic studies and could be the key to explaining the
conflicting nature of the current data.

TABLE 2 | Clinical symptoms and outcomes of COVID-19 case series including abdominal organ transplant recipients.
References

Symptoms
Fever

Fernández-Ruiz
et al. (15)

15/18 (83.3)

Outcomes

Cough

Myalgia

Malaise
/Fatigue

12/18 (66.7)

5/18 (27.8)

4/18 (22.3)

Hospitalized

Pneumoniaa

ICU
admission
or
intubation

AKI

Death

Discharged

15/18 (83.3)

13/18 (72.2)

2/18 (11.1)

N/A

5/18 (27.8)

8/15 (53.3)

Zhu et al. (16)

9/10 (90.0)

9/10 (90.0)

N/A

9/10 (90.0)

10/10 (100.0)

10/10 (100.0)

0/10 (0.0)

N/A

1/10 (10.0)

8/10 (80.0)

Columbia
University (17)

13/15 (86.7)

9/15 (60.0)

2/15 (13.3)

4/15 (26.7)

15/15 (100.0)

9/15 (60.0)

4/15 (26.7)

6/15
(40.0)

1/15 (6.7)

8/15 (53.3)

Pereira et al. (18)

63/90 (70.0)

53/90 (58.9)

22/90 (24.4)

25/90 (27.8)

68/90 (75.6)

68/68 (100.0)

23/90 (25.6)
24/90 (26.7)

N/A

16/90 (17.8)

37/68 (54.4)

Akalin et al. (19)

21/36 (58.3)

19/36 (52.8)

13/36 (36.1)

N/A

28/36 (77.8)

27/36 (75.0)

11/36 (30.6)

6/36
(16.7)

10/36 (27.8)

10/28 (35.8)

Donato et al. (20)

8/8 (100)

N/A

N/A

N/A

5/8 (62.5)

6/8 (75.0)

0/8 (0.0)

0/8 (0.0)

3/5 (60.0)

N/A

a Confirmed

by radiographic findings. ICU, intensive care unit; AKI, acute kidney injury; N/A, not available.
Numbers in parentheses denote percentages.
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Additional dilemmas arise regarding the potential
discontinuation of immunosuppression regimens to improve
their immune response to the infection, which must be
weighed against the potential adverse event of transplant
rejection. Nevertheless, immunosuppression regimens were fully
maintained in many of the reported kidney transplant recipient
cases. Notably, the disease remained mild throughout its course
and patients recovered uneventfully (25, 26, 31, 32). In all these
cases, the authors hypothesized that the immunosuppression
regimens may have prevented the overt immune response,
manifesting as a “cytokine storm,” that is believed to be
responsible for many of the severe manifestations of the disease,
such as acute respiratory distress syndrome and multi-organ
failure (33). In a report from an Italian transplant center, fully
immunosuppressed patients experienced positive outcomes,
while three patients on minimal immunosuppression died
due to COVID-19 (34). Calcineurin inhibitors, in particular,
may also interfere with the life cycle of SARS-CoV-2 (35).
However, maintaining immunosuppression may come at the
cost of fatal nosocomial infections, as in the case of a liver
transplant recipient (36). In addition, confounding factors
such as metabolic abnormalities of long-term transplant
recipients may be responsible for worse outcomes in patients
with low immunosuppression status (34). Cases of mild,
uncomplicated disease course have also been described in spite
of immunosuppressant discontinuation (22, 30, 37). However,
this practice is not risk-free as shown in a liver transplant
recipient who entered a temporary state of rejection after
immunosuppressant discontinuation as part of his COVID-19
management (38).
The interactions between immunosuppressants and antiviral
medication give rise to additional concerns. Tacrolimus is a
drug often used after kidney and liver transplantation and
is metabolized by CYP3A4. Severe toxicity can occur, as
protease inhibitors inhibit this enzyme (39); this includes
lopinavir and ritonavir, which are used together as one
of the standard regimens for the treatment of COVID-19.
A dangerous interaction of this kind was described in a
kidney transplant recipient, while in other cases careful dosage
adjustments were made, immunosuppressants were discontinued
or antivirals were omitted entirely to prevent this adverse
reaction (15, 25–27, 32, 36). Similar interactions may occur
with many other immunosuppressants metabolized by this
pathway. In some cases, immunosuppressants were decreased
or discontinued and corticosteroids were initiated or their
dosages were increased, in an attempt to prevent adverse
drug interactions and disease outcomes, while simultaneously
avoiding graft rejection (30, 32, 36). This practice still remains
controversial. Cumulative data show that corticosteroid use is
associated with worse outcomes in COVID-19, similar to SARS
(40, 41). The limited and conflicting data currently prevent
us from making any definitive conclusions about the role
of corticosteroids and other immunosuppressants during the
management of transplanted COVID-19 patients. The Beijing
working group for liver transplantation currently recommends
that immunosuppressants should not be discontinued unless
severe disease develops and drugs that alter their concentrations,

Frontiers in Medicine | www.frontiersin.org

including lopinavir/ritonavir, should be avoided due to lack of
evidence for their efficacy (42).

WHAT DOES THE PAST HAVE TO SAY?
It is not the first time that humanity faces this kind of threat.
Within the last two decades, two similar viral outbreaks have
occurred, namely the SARS-CoV outbreak in 2003 and the
Middle East Respiratory Syndrome coronavirus (MERS-CoV) in
2012. Both of them, along with SARS-CoV-2, share remarkably
similar characteristics, such as their taxonomy (all being
coronaviruses), zoonotic origin, direct and indirect human-tohuman transmission, pathogenicity, and clinical manifestations
(43, 44). Despite their smaller scale, these outbreaks can teach us
valuable lessons about the possible effects and the management
of the current situation.
The detrimental effects of a global viral outbreak on
abdominal organ transplant programs were observed during
the SARS-CoV (2003) outbreak. According to a report from a
liver transplant program in Hong Kong, transplantations had
to be held off due to a combination of fear for community
spread, lack of ICU beds, and doctors placed in quarantine. As
a result, transplant candidates died while on the waiting list,
and recipients missed elective follow-up appointments in fear
of being infected (45). Similarly to SARS-CoV-2, the underlying
comorbidities and immunocompromised status of transplant
recipients may predispose them to high viral burdens of SARSCoV and atypical clinical presentations (46, 47). The same
pattern has also been observed during the MERS-CoV epidemic
in renal transplant recipients (48).
Interestingly, massive community spread can occur before
appropriate isolation measures are taken, as it has been
previously demonstrated in a liver transplant recipient in
Toronto (49). Transmission from donors remains another
serious concern, which resulted in the development of
appropriate screening tools to classify donors according to
their infection risk, based on previous history and clinical
parameters. Similar protocols were established for potential
recipients (49).

ABDOMINAL ORGAN TRANSPLANTATION
DURING THE COVID-19 PANDEMIC
As COVID-19 rapidly evolved into a full-blown pandemic,
transplant organizations and services around the globe promptly
responded by issuing guidelines and taking appropriate measures
to mitigate the risk of transmission between patients and
medical personnel. These guidelines address three potential
standpoints the epidemic confronts transplantation systems
with; first, the risk of donor-derived SARS-CoV-2 infection,
which although has not been reported thus far in neither
organ or blood product recipients, extensive donor screening
protocols have been implemented in many transplant centers
in pandemic areas. Second, the risk of nosocomial COVID19 infection of the living donor and the transplant candidate
during the transplant hospitalization as the pandemic increases

4
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TABLE 3 | Summary of recommendations from various organizations regarding abdominal organ transplant donors, candidates and recipients.
Population

Subject

Deceased
donors

COVID-19 testing

Testing method
Exclusion from
donation

Donation suspension

Living donors

Routine testing of donors only in areas with significant ongoing community transmission

TTS

Routine testing of donors with epidemiological or clinical risk factors

AST

Routine testing of all donors

ASTS

Both upper (nasopharyngeal/oropharyngeal swab) and lower airway samples (BAL)

AST, TTS

Lower airway sample (BAL)

ASTS

COVID-19 patients

AST, ASTS

High-risk patients according to travel or contact history

AST, TTS

High-risk patients according to clinical symptoms

AST

Intermediate risk patients according to travel/contact history or clinical symptoms and unavailable
COVID-19 testing (only if intestines are used)

AST

Tiered suspension should only be considered in countries with widespread transmission

TTS
AST

Should be considered on a case-by-case basis

ASTS

Routine testing of donors with epidemiological or clinical risk factors

AST

Routine testing of donors if available

TTS

Routine testing of all donors

ASTS

Both upper (nasopharyngeal/oropharyngeal swab) and lower airway samples (BAL)

TTS

Upper (nasopharyngeal/oropharyngeal swab)

AST, ASTS

Any person with respiratory symptoms or fevera

AST, ASTS, TTS

Any person with high-risk travel or contact historya,b

AST, TTS

COVID-19 patients

AST, ASTS

Donation suspension

Should be considered for non-urgent cases

AST, ASTS, TTS

Consultations

Telemedicine or phone consultations should be utilized whenever possible

AST, ASTS

COVID-19 testing

If the patient is considered high-risk for COVID-19 exposure and testing is available

AST

Transplantation
deferment

For COVID-19 patients until ≥ 2 negative samples and symptom resolution

AST

Temporary suspension of all non-urgent cases may be considered

AST, ASTS, TTS

Travel

Avoid all travel in areas with SARS-CoV-2 transmission

TTS

Avoid cruise ships

TTS

Avoid all non-essential travel

AST

Medication

Patients should carry an extended supply of their medicines

AST, ASTS

Symptom
development

Patients should call their transplant centers and avoid going to clinics

AST, ASTS, TTS

COVID-19 testing

Exclusion from
donation

Recipients

Endorsed by

May need to be considered for non-urgent cases

Testing method

Candidates

Current recommendations

BAL, Bronchoalveolar lavage; TTS, The Transplantation Society; AST, American Society of Transplantation, ASTS, American Society of Transplant Surgeons.
a The AST recommends deferment for 28 days beyond symptom resolution plus ≥ 2 negative SARS-CoV-2 tests if high-risk.
b TTS recommends deferment for 14 days.

affected area in Italy (51). Organizations including the American
Society of Transplantation (AST), the American Society of
Transplant Surgeons (ASTS), The Transplantation Society, the
Organ Procurement and Transplantation Network, and the
Association for Organ Procurement Organizations have all issued
similar recommendations (52–56). These recommendations are
presented in Table 3. All of them can be summarized as an
urgent call for transplant services to adopt strict protocols for the
selection and testing of both donors and prospective recipients,
along with appropriate isolation measures. Specifically, the AST
has developed an algorithm, in order to stratify potential donors
according to their SARS-CoV-2 infection risk and currently
suggests that only low-risk donors be considered for organ
procurement, in addition to intermediate-risk donors under
specific circumstances (52). Canada has already implemented this
practice, in a similar manner to the SARS (2003) outbreak, as

the fraction of hospitalized patients being infected. This is more
relevant for the transplant candidate (as they become recipient)
given immunosuppression initiation during the transplant
hospitalization. Third, the system-related risks as the allocated
resources to transplantation are challenged by the system-wide
need for managing the epidemic, including but not limited to
hospital staffing, beds (regular and ICU), and blood products,
thus affecting the availability of such resources for recipients and
deceased donors.
In a Chinese transplant center, an extensive screening protocol
has been established for both potential donors and recipients, as
well as their families and includes their contact and travel history,
clinical and radiological findings, and SARS-CoV-2 laboratory
testing. In addition, strict precaution measures are being taken
by both patients and medical professionals (50). Similar measures
were applied in a transplant program located in a heavily

Frontiers in Medicine | www.frontiersin.org
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previously mentioned (49, 57). The ASTS recommends SARSCoV-2 testing on all deceased donors and advises against
traveling of the donor organ recovery team, suggesting that
organs should be recovered locally instead. If travel is necessary,
extreme precautions measures should be taken (52). These
proposals strongly reflect the severity of the situation, as ASTS
prioritizes measures to decrease transmission in spite of their
potential impact on current quality standards for organ recovery.
Donor availability may sharply decrease as a result of these
restrictions, as documented by a liver transplant center in Italy
(58). An important consideration about the current guidelines is
that there is no true consensus between transplant organizations
globally for any aspect of solid organ transplantation in regards
to COVID-19 (59). The wide variety of different and often
conflicting approaches to patient management reflects the
current lack of data to support a standardized approach with
unanimous support by the scientific community. It becomes
clear that the transplant community is in great need for more
data, not just to understand the effects COVID-19 in transplant
recipients, but more importantly to orchestrate a coordinated
response based on evidence rather than hypotheses.
Meanwhile, the lack of data surrounding many aspects of
COVID-19 disease and its effects on transplant patients further
complicate the situation and may necessitate the application of
more drastic measures. The viability of SARS-CoV-2 in blood
or various organs remains unclear, and this could significantly
affect the donor-to-recipient transmission risk. In a preliminary
report, viral RNAemia was found in 15% of the 41 tested patients
(5). The angiotensin-converting enzyme 2 human cell receptor,
which is implicated in the pathogenicity of SARS-CoV-2, has
been found to be highly expressed in proximal tubule cells of
the kidney, but minimally in liver cells (60). On the other hand,
liver inflammation attributed to COVID-19 has been described
in a liver transplant recipient, suggesting that the virus can affect
the liver and generating concerns about potential donor-recipient
transmission (61). Additional data regarding these aspects of
SARS-CoV-2 could further individualize guidelines for liver and
kidney transplantation.
Current recommendations must be routinely revised, as the
COVID-19 outbreak is rapidly escalating. Kumar et al. recently
proposed a four-staged approach to restrict the activity of
solid organ transplantation programs according to the severity
of the outbreak and its burden on healthcare (57). However,
more radical approaches are also being considered. The AST
has already warned that all non-urgent transplantations might
be temporarily suspended at any time in an effort to control
the situation. England has already moved in this direction by

suspending all elective surgeries over the next 3 months (62).
More recently, India officially suspended all non-urgent liver
transplantations (63). It is likely that many countries will soon
follow this strategy, if they have not done so already. This
situation will lead to ethical dilemmas, where the benefits of
saving a patient’s life must be weighed against the risk of
disease transmission to the patient and the community. The
lack of reliable data regarding immunosuppressed patients,
including transplant recipients, has sparked further controversy
about this decision. The current notion that these patients
are at increased risk for severe disease or death and the
effectiveness of shutting down transplant programs have recently
been disputed (64). Nevertheless, additional factors beyond the
immunocompromised status of transplant recipients, including
but not limited to their age, underlying comorbidities, and
type of transplant, must be taken into account during the
decision-making process. Another concern is that inequalities to
healthcare access, including those surrounding the abdominal
organ transplantation process, may be amplified by the
restrictions put in place due to the pandemic (65).

DISCUSSION
In contrast to other infectious diseases where only the transplant
recipient is at risk, SARS-CoV-2 could rapidly spread amongst
medical personnel, resulting in serious consequences to the
community (66). As a result, it becomes imperative that
both patients and medical professionals strictly adhere to
all appropriate safety measures geared toward minimizing
transmission, in order to ensure that transplant programs can
continue to operate uninterrupted for as long as possible,
without placing the patients or the community at risk.
However, transplant organizations must remain vigilant
and frequently update their recommendations. At the same
time, administrative authorities at a local, regional, and
nationwide level must be ready to respond appropriately
and take all measures necessary to ensure the safety of
public health, including temporary discontinuation of all
non-urgent transplantations.
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